Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 September 2021 | Story Leonie Bolleurs | Photo Sonia Small (Kaleidoscope Studios)
Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact, will be speaking at the International Summit on the Sustainable Development Goals (SDGs) in Africa 2021.

Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact at the University of the Free State (UFS), will be speaking at the three-day International Summit on the Sustainable Development Goals (SDGs) in Africa 2021. The summit will take place as follows:

Date: 13-15 September 2021 
Platform: A virtual gathering (register for the upcoming virtual summit)

Together with a wide array of thought leaders, including specialists, senior researchers, CEOs/directors, and the top structures of international organisations, he will address and engage with an audience of academics, practitioners, government authorities, representatives from civil society, and donors and sponsors from across the globe on the topic Partnerships for impact in Africa (session on 15 September from 12:30 to 14:00).

According to the host of the event, the University of Cape Town, the key aim of the International Summit on the SDGs in Africa is to mobilise collaborative efforts that will accelerate African-led activities in support of achieving the African Union's Agenda 2063 and the United Nations Sustainable Development Goals (SDGs) – a shared blueprint for working towards global peace and prosperity by 2030. The summit is also designed to identify concrete opportunities for research collaboration that will accelerate the achievement of the SDGs and Agenda 2063.

The talks, panel discussions, workshops, and breakout sessions will revolve around clear steps for implementation.

For more information, visit: http://www.sdgsafricasummit.uct.ac.za/

Background of Dr Molapo Qhobela

Dr Qhobela’s leadership and strategic direction have been sought by several large and complex organisations during his career. He is the immediate former Chief Executive Officer (CEO) of the National Research Foundation, and also the former Chair of the Global Research Council as well as the Agricultural Research Council. He is currently the Chairperson of the Tertiary Education and Research Network of South Africa. Dr Qhobela holds a PhD in Plant Pathology from the Kansas State University in the United States of America.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept